REFERENCES
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023-75.
3. Liu H, Li Y, Li Z, Han X, Ren K. Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma. Front Pharmacol. 2023;14:1170344.
4. Boumelha J, de Carné Trécesson S, Law EK, et al. An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Cancer Res. 2022;82:3435-48.
5. Xiao Y, Liu P, Wei J, Zhang X, Guo J, Lin Y. Recent progress in targeted therapy for non-small cell lung cancer. Front Pharmacol. 2023;14:1125547.
6. Laudadio E, Mangano L, Minnelli C. Chemical scaffolds for the clinical development of mutant-selective and reversible fourth-generation EGFR-TKIs in NSCLC. ACS Chem Biol. 2024;19:839-54.
7. Li Z, Zhuang X, Pan CH, et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discov. 2024;14:308-25.
8. Liang J, Bi G, Huang Y, et al. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma. Drug Resist Updat. 2024;73:101057.
9. Puyalto A, Rodríguez-Remírez M, López I, et al. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation. Mol Cancer. 2024;23:78.
10. Hijazo-Pechero S, Alay A, Cordero D, et al. Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications. Mol Oncol. 2024;18:453-70.
11. Naqash AR, McCallen JD, Mi E, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023;11:e007310.
12. Wang C, Yu Q, Song T, et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022;7:289.
13. Moncada R, Barkley D, Wagner F, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 2020;38:333-42.
14. Tan Z, Chen X, Zuo J, Fu S, Wang H, Wang J. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. J Transl Med. 2023;21:223.
15. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411-20.
16. Pozniak J, Pedri D, Landeloos E, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187:166-83.e25.
17. Ravi VM, Will P, Kueckelhaus J, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 2022;40:639-55.e13.
18. Song X, Xiong A, Wu F, et al. Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. J Immunother Cancer. 2023;11:e006234.
19. Ma Y, Deng C, Zhou Y, et al. Polygenic regression uncovers trait-relevant cellular contexts through pathway activation transformation of single-cell RNA sequencing data. Cell Genom. 2023;3:100383.
20. Cao R, Ma B, Wang G, Xiong Y, Tian Y, Yuan L. An epithelial-mesenchymal transition (EMT) preoperative nomogram for prediction of lymph node metastasis in bladder cancer (BLCA). Dis Markers. 2020;2020:8833972.
21. Cao R, Yuan L, Ma B, Wang G, Qiu W, Tian Y. An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med. 2020;24:605-17.
22. Chen S, Zhang N, Shao J, Wang T, Wang X. A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer. J Cancer. 2019;10:5744-53.
23. Jiang Y, Wang Y, Li C, Zou Z, Liang B. Development of an immune-related risk signature in patients with bladder urothelial carcinoma. Biomed Res Int. 2020;2020:5848493.
24. Jiang M, Ren L, Chen Y, et al. Identification of a hypoxia-related signature for predicting prognosis and the immune microenvironment in bladder cancer. Front Mol Biosci. 2021;8:613359.
25. Luo C, Ye W, Hu J, et al. A poliovirus receptor (CD155)-related risk signature predicts the prognosis of bladder cancer. Front Oncol. 2021;11:660273.
26. Na L, Bai Y, Sun Y, et al. Identification of 9-core immune-related genes in bladder urothelial carcinoma prognosis. Front Oncol. 2020;10:1142.
27. Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes. Front Genet. 2020;11:12.
28. Quan J, Zhang W, Yu C, et al. Bioinformatic identification of prognostic indicators in bladder cancer. Biomark Med. 2020;14:1243-54.
29. Shen C, Wang L, Yang X, et al. Construction of a immune-associated genes based prognostic signature in bladder cancer. Artif Cells Nanomed Biotechnol. 2021;49:108-19.
30. Shen C, Liu J, Wang L, Liang Z, Niu H, Wang Y. Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer. Cancer Cell Int. 2020;20:538.
31. Shen C, Xu T, Sun Y, et al. Construction of an immune-associated gene-based signature in muscle-invasive bladder cancer. Dis Markers. 2020;2020:8866730.
32. Wang Z, Tu L, Chen M, Tong S. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. BMC Cancer. 2021;21:692.
33. Wang Y, Chen L, Yu M, et al. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med. 2020;9:7729-41.
34. Wu X, Lv D, Cai C, et al. A TP53-associated immune prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder cancer. Front Immunol. 2020;11:590618.
35. Wu Z, Wen Z, Li Z, Yu M, Ye G. Identification and prognostic value of a glycolysis-related gene signature in patients with bladder cancer. Medicine. 2021;100:e23836.
36. Xing Q, Liu S, Jiang S, Li T, Wang Z, Wang Y. Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA). Transl Androl Urol. 2020;9:2054-70.
37. Yan Y, Huang Z, Cai J, et al. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer. Aging. 2020;13:2780-802.
38. Yan X, Liu XP, Guo ZX, Liu TZ, Li S. Identification of Hub genes associated with progression and prognosis in patients with bladder cancer. Front Genet. 2019;10:408.
39. Yan X, Wu HH, Chen Z, et al. Construction and validation of an autophagy-related prognostic signature and a nomogram for bladder cancer. Front Oncol. 2021;11:632387.
40. Yan X, Fu X, Guo ZX, Liu XP, Liu TZ, Li S. Construction and validation of an eight-gene signature with great prognostic value in bladder cancer. J Cancer. 2020;11:1768-79.
41. Yin H, Zhang C, Gou X, He W, Gan D. Identification of a 13-mRNA signature for predicting disease progression and prognosis in patients with bladder cancer. Oncol Rep. 2020;43:379-94.
42. Yang F, Dong Z, Shen Y, et al. Cribriform growth pattern in lung adenocarcinoma: more aggressive and poorer prognosis than acinar growth pattern. Lung Cancer. 2020;147:187-92.
43. Zhou C, Wang Y, Wang Y, et al. Predicting lung adenocarcinoma prognosis with a novel risk scoring based on platelet-related gene expression. Aging. 2021;13:8706-19.
44. Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.
45. Li F, Zhang H, Huang Y, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059.
46. Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49:361-74.
47. Flórez MM, Fêo HB, da Silva GN, et al. Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response. Vet Comp Oncol. 2017;15:793-807.
48. Sun P, Zhong Z, Lu Q, et al. Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast. Mod Pathol. 2020;33:1945-60.
49. Imamura T, Okamura Y, Ohshima K, et al. Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. BMC Cancer. 2022;22:1046.
50. Kaiser AM, Gatto A, Hanson KJ, et al. p53 governs an AT1 differentiation programme in lung cancer suppression. Nature. 2023;619:851-9.
51. Djulbegovic MB, Uversky VN, Karp CL, Harbour JW. Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia. Int J Biol Macromol. 2022;195:93-101.
52. Lakshmanan I, Salfity S, Seshacharyulu P, et al. MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. Clin Cancer Res. 2017;23:3906-17.
53. Bao X, Li Q, Chen J, et al. Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis. Cancer Immunol Res. 2022;10:811-28.
54. Golino JL, Wang X, Maeng HM, Xie C. Revealing the heterogeneity of the tumor ecosystem of cholangiocarcinoma through single-cell transcriptomics. Cells. 2023;12:862.
55. Zhang J, Li Y, Dai W, et al. Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion. Cancer Immunol Immunother. 2024;73:71.
56. McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20:203-17.
57. Park S, Ock CY, Kim H, et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer. J Clin Oncol. 2022;40:1916-28.
58. Li Y, Shen Z, Chai Z, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. 2023;72:2307-20.
59. Váraljai R, Zimmer L, Al-Matary Y, et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer. 2023;4:1292-308.
60. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:1878-85.
61. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003;22:2135-42.
62. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66:6497-502.
63. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol. 2013;24:309-14.
64. Gong W, Zhang X, Wu J, et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer. 2012;75:374-80.
65. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24:4731-7.
66. Chu G, Ji X, Wang Y, Niu H. Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer. Mol Ther Nucleic Acids. 2023;33:110-26.
67. Ji M, Jo Y, Choi SJ, et al. Plasma metabolomics and machine learning-driven novel diagnostic signature for non-alcoholic steatohepatitis. Biomedicines. 2022;10:1669.
68. Zhang J, He S, Ying H. Refining molecular subtypes and risk stratification of ovarian cancer through multi-omics consensus portfolio and machine learning. Environ Toxicol. 2024;Online ahead of print.
